Nuchal scan

Last updated
Nuchal scan
Nuchal translucency Dr. Wolfgang Moroder.jpg
Measurements of fetal nuchal translucency, nasal bone and facial angle according to the standards of the Fetal Medicine Foundation
Synonyms Nuchal translucency
PurposeUsed to screen for abnormalities in a developing fetus

A nuchal scan or nuchal translucency (NT) scan/procedure is a sonographic prenatal screening scan (ultrasound) to detect chromosomal abnormalities in a fetus, though altered extracellular matrix composition and limited lymphatic drainage can also be detected. [1]

Contents

Since chromosomal abnormalities can result in impaired cardiovascular development, a nuchal translucency scan is used as a screening, rather than diagnostic, tool for conditions such as Down syndrome, Patau syndrome, Edwards Syndrome, and non-genetic body-stalk anomaly. [2]

There are two distinct measurements: the size of the nuchal translucency and the thickness of the nuchal fold. Nuchal translucency size is typically assessed at the end of the first trimester, between 11 weeks 3 days and 13 weeks 6 days of pregnancy. [3] Nuchal fold thickness is measured towards the end of the second trimester. As nuchal translucency size increases, the chances of a chromosomal abnormality and mortality increase; 65% of the largest translucencies (>6.5mm) are due to chromosomal abnormality, while fatality is 19% at this size. [2] A nuchal scan may also help confirm both the accuracy of the pregnancy dates and the fetal viability.

Indication

All women, regardless their age, have a small chance of delivering a baby with a physical or cognitive disability. The nuchal scan helps physicians estimate the chance of the fetus having Down syndrome or other abnormalities more accurately than by maternal age alone.

Down syndrome

Enlarged NT and absent nasal bone in a fetus at 11 weeks with Down syndrome Nuchal edema in Down Syndrome Dr. W. Moroder.jpg
Enlarged NT and absent nasal bone in a fetus at 11 weeks with Down syndrome

Overall, the most common chromosomal disorder is Down syndrome (trisomy 21). The likelihood rises with maternal age from 1 in 1400 pregnancies below age 25, to 1 in 350 at age 35, to 1 in 200 at age 40. [4]

Until recently, the only reliable ways to determine if the fetus has a chromosomal abnormality was to have an invasive test such as amniocentesis or chorionic villus sampling, but such tests carry a risk of causing a miscarriage estimated variously as ranging between 1%[ citation needed ] or 0.06%. [5] Based on maternal age, some countries offer invasive testing to women over 35; others to the oldest 5% of pregnant women. [6] Most women, especially those with a low chance of having a child with Down syndrome, may wish to avoid the risk to the fetus and the discomfort of invasive testing. In 2011, Sequenom announced the launch of MaterniT21, a non-invasive blood test with a high level of accuracy in detecting Down syndrome (and a handful of other chromosomal abnormalities). As of 2015, there are five commercial versions of this screen (called cell-free fetal DNA screening) available in the United States.[ citation needed ]

Blood testing is also used to look for abnormal levels of alphafetoprotein or hormones. The results of all three factors may indicate a higher chance of Down Syndrome. If this is the case, the woman may be advised to have a more reliable screen such as cell-free fetal DNA screening or an invasive diagnostic test (such as chorionic villus sampling or amniocentesis).

Screening for Down syndrome by a combination of maternal age and thickness of nuchal translucency in the fetus at 11–14 weeks of gestation was introduced in the 1990s. [7] This method identifies about 75% of affected fetuses while screening about 5% of pregnancies. Natural fetal loss after positive diagnosis at 12 weeks is about 30%. [6]

Other chromosomal defects

Other common chromosomal defects that cause a thicker nuchal translucency are[ citation needed ]

Other defects with normal karyotype

In fetuses with a normal number of chromosomes, a thicker nuchal translucency is associated with other fetal defects and genetic syndromes. [8]

Procedure

Nuchal scan (NT procedure) is performed between 11 and 14 weeks of gestation, because the accuracy is best in this period. The scan is obtained with the fetus in sagittal section and a neutral position of the fetal head (neither hyperflexed nor extended, either of which can influence the nuchal translucency thickness). The fetal image is enlarged to fill 75% of the screen, and the maximum thickness is measured, from leading edge to leading edge. It is important to distinguish the nuchal lucency from the underlying amniotic membrane. [9]

Normal thickness depends on the crown-rump length (CRL) of the fetus. Among those fetuses whose nuchal translucency exceeds the normal values, there is a relatively high risk of significant abnormality.

Accuracy

An increased nuchal translucency increases the probability that the fetus will be affected by a chromosomal abnormality, congenital cardiac defects, or intrauterine fetal demise. Typically, nuchal translucency alone is not sufficient as a screening test for chromosomal abnormalities. [3]

How to define a normal or abnormal nuchal translucency measurement can be difficult. The use of a single millimeter cutoff (such as 2.5 or 3.0 mm) is inappropriate because nuchal translucency measurements normally increases with gestational age (by approximately 15% to 20% per gestational week from 10 to 13 weeks). [10] At 12 weeks of gestational age, an "average" nuchal thickness of 2.18mm has been observed; however, up to 13% of chromosomally normal fetuses present with a nuchal translucency of greater than 2.5mm. Thus for even greater accuracy of predicting risks, the outcome of the nuchal scan may be combined with the results of simultaneous maternal blood tests. In pregnancies affected by Down syndrome there is a tendency for the levels of human chorionic gonadotropin (hCG) to be increased and pregnancy-associated plasma protein A (PAPP-A) to be decreased.

The advantage of nuchal scanning over the previous use of just biochemical blood profiling is mainly the reduction in false positive rates. [11]

Nuchal scanning alone detects 62% of all Down syndrome (sensitivity) with a false positive rate of 5.0%; the combination with blood testing gives corresponding values of 73% and 4.7%. [12]

In another study values of 79.6% and 2.7% for the combined screening were then improved with the addition of second trimester ultrasound scanning to 89.7% and 4.2% respectively. [13] A further study reported detection of 88% for trisomy 21 (Down syndrome) and 75% for trisomy 18 (Edwards syndrome), with a 3.3% false-positive rate. [14] Finally, using the additional ultrasound feature of an absent nasal bone can further increase detection rates for Down syndrome to more than 95%. [15]

When screening is positive, chorionic villus sampling (CVS) or amniocentesis testing is required to confirm the presence of a genetic abnormality. However this procedure carries a small risk of miscarriage so prior screening with low false positive rates are needed to minimize the chance of miscarrying.

Development of nuchal translucency

The actual anatomic structure whose fluid is seen as translucency is likely the normal skin at the back of the neck, which either may become edematous or in some cases filled with fluid by dilated lymphatic sacs due to altered normal embryological connections. [16]

The translucent area measured (the nuchal translucency) is only useful to measure between 11 and 14 weeks of gestation, when the fetal lymphatic system is developing and the peripheral resistance of the placenta is high. After 14 weeks the lymphatic system is likely to have developed sufficiently to drain away any excess fluid, and changes to the placental circulation will result in a drop in peripheral resistance. So after this time any abnormalities causing fluid accumulation may seem to correct themselves and can thus go undetected by nuchal scanning.

The buildup in fluid is due to a blockage of fluid in the developing fetal lymphatic system. Progressive increase in the width of the translucent area during the 11- to 14-week measurement period is thus indicative of congenital lymphedema. [17]

Nuchal fold thickness

Correct modified axial plane for the measurement of the nuchal fold in the second trimester . Nuchal fold measurement on the TC plane Dr. Moroder.jpg
Correct modified axial plane for the measurement of the nuchal fold in the second trimester .

Nuchal translucency testing is distinctly different from and should not be confused with nuchal thickness testing. At the end of the first trimester (14 weeks), the nuchal translucency can no longer be seen and instead the nuchal fold thickness is measured between 16 and 24 weeks gestation. The fold is more focal and at the level of the posterior fossa. This measurement has a higher threshold of normal, although the implications of increased thickness are similar to those of translucency. The nuchal fold thickness is considered normal if under 5mm between 16 and 18 weeks gestation and under 6mm between 18 and 24 weeks gestation. An increased thickness corresponds to increased risk for aneuploidy and other fetal abnormalities.

See also

Related Research Articles

Obstetrics is the field of study concentrated on pregnancy, childbirth and the postpartum period. As a medical specialty, obstetrics is combined with gynecology under the discipline known as obstetrics and gynecology (OB/GYN), which is a surgical field.

<span class="mw-page-title-main">Amniocentesis</span> Sampling of amniotic fluid done mainly to detect fetal chromosomal abnormalities

Amniocentesis is a medical procedure used primarily in the prenatal diagnosis of genetic conditions. It has other uses such as in the assessment of infection and fetal lung maturity. Prenatal diagnostic testing, which includes amniocentesis, is necessary to conclusively diagnose the majority of genetic disorders, with amniocentesis being the gold-standard procedure after 15 weeks' gestation.

<span class="mw-page-title-main">Obstetric ultrasonography</span> Use of medical ultrasonography in pregnancy

Obstetric ultrasonography, or prenatal ultrasound, is the use of medical ultrasonography in pregnancy, in which sound waves are used to create real-time visual images of the developing embryo or fetus in the uterus (womb). The procedure is a standard part of prenatal care in many countries, as it can provide a variety of information about the health of the mother, the timing and progress of the pregnancy, and the health and development of the embryo or fetus.

<span class="mw-page-title-main">Prenatal testing</span> Testing for diseases or conditions in a fetus

Prenatal testing is a tool that can be used to detect some birth defects at various stages prior to birth. Prenatal testing consists of prenatal screening and prenatal diagnosis, which are aspects of prenatal care that focus on detecting problems with the pregnancy as early as possible. These may be anatomic and physiologic problems with the health of the zygote, embryo, or fetus, either before gestation even starts or as early in gestation as practicable. Screening can detect problems such as neural tube defects, chromosome abnormalities, and gene mutations that would lead to genetic disorders and birth defects, such as spina bifida, cleft palate, Down syndrome, trisomy 18, Tay–Sachs disease, sickle cell anemia, thalassemia, cystic fibrosis, muscular dystrophy, and fragile X syndrome. Some tests are designed to discover problems which primarily affect the health of the mother, such as PAPP-A to detect pre-eclampsia or glucose tolerance tests to diagnose gestational diabetes. Screening can also detect anatomical defects such as hydrocephalus, anencephaly, heart defects, and amniotic band syndrome.

<span class="mw-page-title-main">Chorionic villus sampling</span> Type of prenatal diagnosis done to determine chromosomal or genetic disorders in the fetus

Chorionic villus sampling (CVS), sometimes called "chorionic villous sampling", is a form of prenatal diagnosis done to determine chromosomal or genetic disorders in the fetus. It entails sampling of the chorionic villus and testing it for chromosomal abnormalities, usually with FISH or PCR. CVS usually takes place at 10–12 weeks' gestation, earlier than amniocentesis or percutaneous umbilical cord blood sampling. It is the preferred technique before 15 weeks.

<span class="mw-page-title-main">Choroid plexus cyst</span> Medical condition

Choroid plexus cysts (CPCs) are cysts that occur within choroid plexus of the brain. They are the most common type of intraventricular cyst, occurring in 1% of all pregnancies.

The triple test, also called triple screen, the Kettering test or the Bart's test, is an investigation performed during pregnancy in the second trimester to classify a patient as either high-risk or low-risk for chromosomal abnormalities.

Echogenic intracardiac focus (EIF) is a small bright spot seen in the baby's heart on an ultrasound exam. This is thought to represent mineralization, or small deposits of calcium, in the muscle of the heart. EIFs are found in about 3–5% of normal pregnancies and cause no health problems.

<span class="mw-page-title-main">Cystic hygroma</span> Human disease

A cystic hygroma is an abnormal growth that usually appears on a baby's neck or head. It consists of one or more cysts and tends to grow larger over time. The disorder usually develops while the fetus is still in the uterus, but can also appear after birth.

The Pallister–Killian syndrome (PKS), also termed tetrasomy 12p mosaicism or the Pallister mosaic aneuploidy syndrome, is an extremely rare and severe genetic disorder. PKS is due to the presence of an extra and abnormal chromosome termed a small supernumerary marker chromosome (sSMC). sSMCs contain copies of genetic material from parts of virtually any other chromosome and, depending on the genetic material they carry, can cause various genetic disorders and neoplasms. The sSMC in PKS consists of multiple copies of the short arm of chromosome 12. Consequently, the multiple copies of the genetic material in the sSMC plus the two copies of this genetic material in the two normal chromosome 12's are overexpressed and thereby cause the syndrome. Due to a form of genetic mosaicism, however, individuals with PKS differ in the tissue distributions of their sSMC and therefore show different syndrome-related birth defects and disease severities. For example, individuals with the sSMC in their heart tissue are likely to have cardiac structural abnormalities while those without this sSMC localization have a structurally normal heart.

<span class="mw-page-title-main">Kypros Nicolaides</span> Greek-Cypriot fetal medicine specialist

Kyprianos "Kypros" Nicolaides is a Greek Cypriot physician of British citizenship, Professor of Fetal Medicine at King's College Hospital, London. He is one of the pioneers of fetal medicine and his discoveries have revolutionised the field. He was elected to the US National Academy of Medicine in 2020 for 'improving the care of pregnant women worldwide with pioneering rigorous and creative approaches, and making seminal contributions to prenatal diagnosis and every major obstetrical disorder'. This is considered to be one of the highest honours in the fields of health and medicine and recognises individuals who have demonstrated outstanding professional achievement and commitment to service.

The genetics and abortion issue is an extension of the abortion debate and the disability rights movement. Since the advent of forms of prenatal diagnosis, such as amniocentesis and ultrasound, it has become possible to detect the presence of congenital disorders in the fetus before birth. Specifically, disability-selective abortion is the abortion of fetuses that are found to have non-fatal mental or physical defects detected through prenatal testing. Many prenatal tests are now considered routine, such as testing for Down syndrome. Women who are discovered to be carrying fetuses with disabilities are often faced with the decision of whether to abort or to prepare to parent a child with disabilities.

Confined placental mosaicism (CPM) represents a discrepancy between the chromosomal makeup of the cells in the placenta and the cells in the fetus. CPM was first described by Kalousek and Dill in 1983. CPM is diagnosed when some trisomic cells are detected on chorionic villus sampling and only normal cells are found on a subsequent prenatal test, such as amniocentesis or fetal blood sampling. In theory, CPM is when the trisomic cells are found only in the placenta. CPM is detected in approximately 1-2% of ongoing pregnancies that are studied by chorionic villus sampling (CVS) at 10 to 12 weeks of pregnancy. Chorionic villus sampling is a prenatal procedure which involves a placental biopsy. Most commonly when CPM is found it represents a trisomic cell line in the placenta and a normal diploid chromosome complement in the baby. However, the fetus is involved in about 10% of cases.

<span class="mw-page-title-main">Circumvallate placenta</span> Medical condition

Circumvallate placenta is a rare condition affecting about 1-2% of pregnancies, in which the amnion and chorion fetal membranes essentially "double back" on the fetal side around the edges of the placenta. After delivery, a circumvallate placenta has a thick ring of membranes on its fetal surface. Circumvallate placenta is a placental morphological abnormality associated with increased fetal morbidity and mortality due to the restricted availability of nutrients and oxygen to the developing fetus.

<span class="mw-page-title-main">Single umbilical artery</span> Medical condition

Occasionally, there is a single umbilical artery (SUA) present in the umbilical cord, as opposed to the usual two. This is sometimes also called a two-vessel umbilical cord, or two-vessel cord. Approximately, this affects between 1 in 100 and 1 in 500 pregnancies, making it the most common umbilical abnormality. Its cause is not known.

Ravinder (Rav) Dhallan is the chairman and chief executive officer of Ravgen.

Cell-free fetal DNA (cffDNA) is fetal DNA that circulates freely in the maternal blood. Maternal blood is sampled by venipuncture. Analysis of cffDNA is a method of non-invasive prenatal diagnosis frequently ordered for pregnant women of advanced maternal age. Two hours after delivery, cffDNA is no longer detectable in maternal blood.

The anomaly scan, also sometimes called the anatomy scan, 20-week ultrasound, or level 2 ultrasound, evaluates anatomic structures of the fetus, placenta, and maternal pelvic organs. This scan is an important and common component of routine prenatal care. The function of the ultrasound is to measure the fetus so that growth abnormalities can be recognized quickly later in pregnancy, to assess for congenital malformations and multiple pregnancies, and to plan method of delivery.

Noninvasive prenatal testing (NIPT) is a method used to determine the risk for the fetus being born with certain chromosomal abnormalities, such as trisomy 21, trisomy 18 and trisomy 13. This testing analyzes small DNA fragments that circulate in the blood of a pregnant woman. Unlike most DNA found in the nucleus of a cell, these fragments are not found within the cells, instead they are free-floating, and so are called cell free fetal DNA (cffDNA). These fragments usually contain less than 200 DNA building blocks and arise when cells die, and their contents, including DNA, are released into the bloodstream. cffDNA derives from placental cells and is usually identical to fetal DNA. Analysis of cffDNA from placenta provides the opportunity for early detection of certain chromosomal abnormalities without harming the fetus.

Beryl Rice Benacerraf was an American radiologist and professor of obstetrics, gynecology and reproductive biology and radiology at Harvard Medical School. She was a pioneer in the use of prenatal ultrasound to diagnose fetal abnormalities, including Down syndrome. In 2021, she was recognized as a "Giant in Obstetrics and Gynecology" by the American Journal of Obstetrics & Gynecology.

References

  1. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH (2005-04-06). "Increased nuchal translucency with normal karyotype". American Journal of Obstetrics and Gynecology. 192 (4): 1005–1021. doi:10.1016/j.ajog.2004.12.093. PMID   15846173.
  2. 1 2 Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH (2005-04-06). "Increased nuchal translucency with normal karyotype". American Journal of Obstetrics and Gynecology. 192 (4): 1005–1021. doi:10.1016/j.ajog.2004.12.093. PMID   15846173.
  3. 1 2 Gomella, Tricia; Cunningham, M. (2013). Neonatology : management, procedures, on-call problems, diseases, and drugs. Gomella, Tricia Lacy, Cunningham, M. Douglas, Eyal, Fabien G. (7th ed.). New York. ISBN   9780071768016. OCLC   830349840.{{cite book}}: CS1 maint: location missing publisher (link)
  4. "Down Syndrome - Signs and Symptoms". Ucsfhealth.org. 2008-03-21. Retrieved 2009-03-10.
  5. Eddleman, K. Obstetrics & Gynecology, November 2006; vol 108: pp 1067-1072, quoted at webmd.com
  6. 1 2 Nicolaides KH, Sebire NJ, Snijders RJ, Ximenes RL (2001). "Diploma in Fetal Medicine & ISUOG Educational Series: 11 - 14 weeks scan: NT and Chromosomal defects". Centrus. Retrieved 2009-06-19.
  7. Russo, Melissa L.; Blakemore, Karin J. (June 2014). "A historical and practical review of first trimester aneuploidy screening". Seminars in Fetal & Neonatal Medicine. 19 (3): 183–187. doi:10.1016/j.siny.2013.11.013. PMC   6596981 . PMID   24333205.
  8. Nicolaides KH, Sebire NJ, Snijders RJ, Ximenes RL (2001). "Diploma in Fetal Medicine & ISUOG Educational Series: 11 - 14 weeks scan: Increased NT and normal karyotype". Centrus. Retrieved 2009-06-19.
  9. Mehrjardi, Mohammad Zare (2015). "Additional ultrasonographic markers in the first trimester screening (11wk to 13wk+6d) (PDF Download Available)". ResearchGate. doi:10.13140/rg.2.2.32248.85761/1.
  10. Malone, F.D. (13 August 2005). "Nuchal Translucency-Based Down Syndrome Screening: Barriers to Implementation". Seminars in Perinatology. 29 (4): 272–276. doi:10.1053/j.semperi.2005.05.002. PMID   16104681.
  11. Babbur V, Lees CC, Goodburn SF, Morris N, Breeze AC, Hackett GA (2005). "Prospective audit of a one-centre combined nuchal translucency and triple test programme for the detection of trisomy 21". Prenat. Diagn. 25 (6): 465–9. doi:10.1002/pd.1163. PMID   15966036. S2CID   24633288.
  12. Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H (2003). "First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers". Prenat. Diagn. 23 (10): 833–6. doi: 10.1002/pd.700 . PMID   14558029. S2CID   33122084.
  13. Rozenberg P, Bussières L, Chevret S, et al. (2007). "[Screening for Down syndrome using first-trimester combined screening followed by second trimester ultrasound examination in an unselected population]". Gynecol Obstet Fertil (in French). 35 (4): 303–11. doi:10.1016/j.gyobfe.2007.02.004. PMID   17350315.
  14. Borrell A, Casals E, Fortuny A, et al. (2004). "First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional study". Prenat. Diagn. 24 (7): 541–5. doi:10.1002/pd.949. PMID   15300745. S2CID   25354046.
  15. Nicolaides KH, Wegrzyn P (2005). "[First trimester diagnosis of chromosomal defects]". Ginekol. Pol. (in Polish). 76 (1): 1–8. PMID   15844559.
  16. Callen, Peter W. "Nuchal Translucency". Ultrasound Educational Press. Retrieved 2014-11-05.
  17. Souka, A. P.; Krampl, E.; Geerts, L.; Nicolaides, K. H. (September 5, 2002). "Congenital lymphedema presenting with increased nuchal translucency at 13 weeks of gestation". Prenatal Diagnosis. 22 (2): 91–92. doi:10.1002/pd.104. PMID   11857608. S2CID   35812389.
  18. Beryl Benacerraf The significance of the nuchal fold in the second trimester fetus Prenatal Diagnosis . 2002 Sep;22(9):798-801.